Pending Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-47. (Canceled)

Claim 48. (Previously Presented): A pharmaceutical composition comprising:

(a) a carrier; and

(b) a mannose-binding protein which is a lectin comprising a heterodimer of a first polypeptide and a second polypeptide, wherein the first polypeptide has a molecular weight of about 12-20kDa, and wherein the second polypeptide has a molecular weight of about 15-20kDa;

wherein the lectin can be obtained from a legume selected from the group consisting of *Phaseolus vulgaris, Dolichos lab lab,* and *Vigna senensis.*

Claim 49. (Previously Presented): The pharmaceutical composition of claim 48, wherein the lectin is obtained from an extract of a plant selected from the group consisting of *Phaseolus vulgaris, Dolichos lab lab,* and *Vigna senensis.*

Claim 50. (Previously Presented): The pharmaceutical composition of claim 48, wherein the lectin is capable of binding the flk2/flt3 receptor.

Claim 51. (Previously Presented): The pharmaceutical composition of claim 48, wherein the lectin is capable of stimulating proliferation of NIH 3T3 fibroblasts expressing the flk2/flt3 receptor in an IL1-dependent manner.

Claim 52. (Previously Presented): The pharmaceutical composition of claim 48, wherein the lectin is capable of preserving progenitor cells.

Claim 53. (Previously Presented): The pharmaceutical composition of claim 52, wherein the progenitor cells are at least unipotent progenitor cells.

Claim 54. (Previously Presented): The pharmaceutical composition of claim 52, wherein the progenitor cells are pluripotent progenitor cells.

Claim 55. (Previously Presented): The pharmaceutical composition of claim 52, wherein the progenitor cells are totipotent progenitor cells.

Claim 56. (Previously Presented): The pharmaceutical composition of claim 52, wherein the progenitor cells comprise hematopoietic progenitor cells.

Claim 57. (Previously Presented): The pharmaceutical composition of claim 52, wherein the progenitor cells comprise human $CD34^+$ cells.

Claim 58. (Previously Presented): The pharmaceutical composition of claim 52, wherein the progenitor cells comprise murine fetal liver $CD34^+$ cells.

Claim 59. (Previously Presented): The pharmaceutical composition of claim 56, wherein the progenitor cells express the CD34 antigen.

Claim 60. (Previously Presented): The pharmaceutical composition of claim 56, wherein the progenitor cells express the flk2/flt3 receptor.

Claim 61. (Previously Presented): The pharmaceutical composition of claim 48, wherein the lectin is capable of preserving cells modified to express the flk2/flt3 receptor on their surface.

Claim 62. (Previously Presented): The pharmaceutical composition of claim 52, wherein the progenitor cells are selected from the group consisting of nerve, muscle, skin, gut, bone, kidney, liver, pancreas or thymus progenitor cells.